BofA warns Fed risks policy mistake with early rate cuts
Replimune Group (NASDAQ:REPL) Chief Financial Officer Emily Luisa Hill sold 9,154 shares of common stock on August 15, 2025, at a price of $5.37, for a total transaction value of $49,156. The transaction comes amid challenging market conditions for the $410 million market cap company, whose shares have declined over 63% in the past six months, according to InvestingPro data.
Following the transaction, Hill directly owns 134,368 shares of Replimune Group. The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, according to a footnote in the SEC filing. While the company maintains a strong liquidity position with more cash than debt and a current ratio of 6.94, InvestingPro analysis reveals 11 additional key insights about the company’s financial health and market position.
In other recent news, Replimune Group has faced significant developments following the FDA’s decision on its RP1 treatment for melanoma. The company received a Complete Response Letter (CRL) from the FDA, indicating that the application for the treatment cannot be approved in its current form. This decision led to multiple analyst actions, including Jefferies lowering its price target for Replimune from $10 to $8 while maintaining a Buy rating. In contrast, Cantor Fitzgerald upgraded Replimune from Neutral to Overweight following a change in leadership at the FDA’s Center for Biologics Evaluation and Research. However, BMO Capital downgraded the stock to Underperform and drastically reduced its price target from $27 to $2. Barclays (LON:BARC) also downgraded Replimune, changing its rating to Equalweight and cutting its price target from $17 to $3. These actions reflect the mixed reactions from analysts regarding Replimune’s recent regulatory challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.